Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IVAC MUTANOME, RBL001/RBL002 · 1 trial · 1 indication
Number of Patients with adverse events, total number of adverse events
| Arm | Type | Description |
|---|---|---|
| IVAC MUTANOME RBL001/RBL002 | EXPERIMENTAL | All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally. |
| Name | Type | Description |
|---|---|---|
| IVAC MUTANOME, RBL001/RBL002 | BIOLOGICAL | Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002. |
Inclusion Criteria: * Malignant Melanoma, resectable stage IIIA-C and IV (AJCC 2009 melanoma classification) * Patients with unresectable Malignant Melanoma stage IIIA-C in complete remission, partial remission or stable disease after treatment with vemurafenib or patients with slow progressive dis...
Top 20 of 51 competitors
IVAC MUTANOME is an investigational cancer immunotherapy being studied for the treatment of melanoma. It is a personalized vaccine designed to target specific mutations in a patient's tumor. The drug is currently in Phase 1 clinical development and has completed a clinical trial in patients with melanoma.
IVAC MUTANOME is a personalized cancer vaccine that targets neoantigens, which are unique mutations present on a patient's tumor cells. By targeting these specific mutations, the vaccine aims to stimulate the immune system to recognize and attack cancer cells. This approach is tailored to each individual patient's tumor profile.
IVAC MUTANOME is being developed by BioNTech SE, a biotechnology company focused on immunotherapies. BioNTech is publicly traded on the NASDAQ under the ticker symbol BNTX. The company is conducting clinical trials to evaluate the safety and efficacy of this personalized cancer vaccine in melanoma patients.
IVAC MUTANOME is currently in Phase 1 clinical development. A Phase 1 trial has been completed, which was designed to assess the safety, tolerability, and preliminary efficacy of the vaccine in patients with melanoma. The drug is still investigational and has not been approved by regulatory authorities.
IVAC MUTANOME has been studied in a Phase 1 clinical trial with the identifier NCT02035956. This completed trial enrolled 15 patients with melanoma and was conducted in Austria and Germany. The study was uncontrolled, meaning there was no comparison group, and it included adult patients aged 18 years and older.
Yes, IVAC MUTANOME is also known as RBL001/RBL002. These names refer to the same investigational personalized cancer vaccine being developed by BioNTech SE for the treatment of melanoma. The drug is in Phase 1 clinical development and has completed a clinical trial in patients with this condition.